ENTA Enanta Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ENTA matters now
Enanta Pharmaceuticals, Inc. (ENTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.25 with -1.66% on the session and $330.8M in market capitalization; recent performance reads 1-month -7.99% and YTD -19.72%.
The latest financial table shown here is Q2 2026, with revenue of $17.2M, net income of $-13.1M, and EPS of $-0.45. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.3%.
The latest indexable market news headline is "Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $54.00; recent insider activity includes CARTER BRUCE L A filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.32
P/S
4.25
EV/EBITDA
-9.57
DCF Value
$-60.97
FCF Yield
-3.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.3%
Operating Margin
-87.2%
Net Margin
-89.6%
ROE
-64.0%
ROA
-19.7%
ROIC
-19.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $17.2M | $-13.1M | $-0.45 |
| Q1 2026 | $18.6M | $-11.9M | $-0.56 |
| Q4 2025 | $15.1M | $-18.7M | $-0.87 |
| FY 2025 | $65.3M | $-81.9M | $-3.84 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$48.20
Target (Median)
$54.00
Target Range
$20.00 - $87.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.99
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.